NEW YORK, March 19, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), WellCare Health
Plans, Inc. (NYSE: WCG), Zogenix, Inc. (NASDAQ: ZGNX), Orexigen
Therapeutics, Inc. (NASDAQ: OREX), and XOMA Corporation (NASDAQ:
XOMA). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at: http://www.AnalystsReview.com/register
Keryx Biopharmaceuticals Inc. Analyst Notes
On March 12, 2014, Keryx
Biopharmaceuticals Inc. (Keryx) reported its Q4 2013 and full-year
2013 financial results. Net loss for Q4 2013 was $17.7 million or $0.21 per diluted share, compared to net loss of
$6.6 million or $0.09 per diluted share in Q4 2012. Full-year
2013 net loss was $46.7 million or
$0.58 per diluted share, compared to
net loss of $22.7 million or
$0.32 per diluted share in full-year
2012. According to the Company, as on December 31, 2013, the Keryx had cash and cash
equivalents of $55.7 million, as
compared to $14.7 million as recorded
on December 31, 2012. The full
analyst notes on Keryx Biopharmaceuticals Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/03192014/KERX/report.pdf
WellCare Health Plans, Inc. Analyst Notes
On March 10, 2014, WellCare Health
Plans, Inc. (WellCare) announced that it is working with
MyHealthDirect to make scheduling doctors' appointments easier and
more convenient for its members and health care providers in
Georgia. According to the Company,
WellCare Medicaid, and Medicare Advantage members who are patients
of providers that participate in the program will be able to work
directly with WellCare representatives for appointment scheduling,
immediate appointment confirmation and to receive text and email
appointment reminders. Roman Kulich,
WellCare's Region President for Georgia and South
Carolina, stated, "WellCare is working to improve our
members' access to care by providing solutions that streamline the
process. This tool is another way that we are making it easier for
our members to get the quality care they need, while offering
increased convenience and administrative savings for providers, and
reducing overall costs." The full analyst notes on WellCare Health
Plans, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03192014/WCG/report.pdf
Zogenix, Inc. Analyst Notes
On March 7, 2014, Zogenix, Inc.
(Zogenix) announced that the American Academy of Pain Medicine
(AAPM) has presented Marsha R.
Stanton, Ph.D., RN, Executive Director of Medical Affairs at
Zogenix, with the Distinguished Service Award. According to the
Company, the recognition is given annually to honor an individual
for their outstanding commitment and contributions to the field of
pain medicine and the AAPM. Bradley S.
Galer, M.D., Executive Vice President and Chief Medical
Officer of Zogenix, stated, "We congratulate Dr. Stanton on
receiving this prestigious award and are proud to have her as part
of our Medical Affairs team. She offers a wealth of experience and
insight into pain medicine and we look forward to her leadership
and guidance as we continue to deliver on our mission of developing
and commercializing therapies that address specific clinical needs
for people living with pain-related conditions." The full analyst
notes on Zogenix, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03192014/ZGNX/report.pdf
Orexigen Therapeutics, Inc. Analyst Notes
On March 12, 2014, Orexigen
Therapeutics, Inc. (Orexigen Therapeutics) announced its Q4 2013
and full-year 2013 financial results. Total revenues remained flat
at $0.9 million and $3.4 million for Q4 2013 and full-year 2013,
respectively. Net loss for Q4 2013 was $21.5
million or $0.21 per diluted
share, compared to net loss of $32.5
million or $0.41 per diluted
share in Q4 2012. Net loss for full year 2013 was $77.7 million or $0.80 per diluted share, compared to net loss of
$90.1 million or $1.27 per diluted share in full year 2012.
Michael Narachi, CEO of Orexigen
Therapeutics, stated, "We expect 2014 will be a transformative year
for Orexigen with the following key catalysts: a US approval, a
well resourced US primary care launch by Takeda, a positive CHMP
opinion, an EU approval, and progress toward a partnership to
commercialize NB32 outside North
America." The full analyst notes on Orexigen Therapeutics,
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03192014/OREX/report.pdf
XOMA Corporation Analyst Notes
On March 4, 2014, XOMA Corporation
(XOMA) reported its Q4 2013 and full-year 2013 financial results.
Q4 2013 total revenues went up by 69.6% YoY to $12.5 million, while full-year 2013 total
revenues went up by 4.9% YoY to $35.5
million. Net loss for Q4 2013 was $52.3 million or $0.55 per diluted share, compared to Q4 2012 net
income of $2.4 million or
$0.03 per diluted share. Full-year
2013 net loss was $124.1 million or
$1.43 per diluted share, compared to
full-year 2012 net loss of $71.1
million or $1.10 per diluted
share. According to XOMA, it anticipates cash used in ongoing
activities during 2014 to be c. $55.0
million to $60.0 million, primarily reflecting the costs
associated with conducting the gevokizumab three Phase 3 clinical
trials in the EYEGUARD program and the costs associated with
conducting a Phase 3 clinical trial in patients with pyoderma
gangrenosum. The full analyst notes on XOMA Corporation are
available to download free of charge at:
http://www.AnalystsReview.com/03192014/XOMA/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
-
For any urgent concerns or inquiries,
please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.AnalystsReview.com/
SOURCE Analysts Review